Nuvation Bio registers Phase 1 famotidine interaction study for taletrectinib
A new trial will test how the acid reducer famotidine affects taletrectinib's pharmacokinetics in healthy adults, ahead of enrollment.
This week's only update is a newly registered early-phase trial for Nuvation Bio's taletrectinib.
- Nuvation Bio registered a Phase 1 open-label trial to evaluate the effect of famotidine on the pharmacokinetics, safety and tolerability of taletrectinib in healthy adult participants.1 The study, NCT07742384, is not yet recruiting, with an estimated enrollment of 56 participants1 and an estimated start date of 2026-08-01.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.